A Phase 4 interventional study of valsartan and amlodipine in Hypertension and Diastolic Dysfunction, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-04-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 65th largest by enrollment of the 139 interventional ones that give a count, is one of 23 that started in 2006, is one of 67 in phase 4, and was the 84th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 23 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 229 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 127th largest by enrollment of the 222 interventional ones that give a count, is one of 32 that started in 2006, is one of 67 in phase 4, and was the 124th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)\<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of \<140 mmHg on the intrinsic diastolic properties of the myocardium in patients with hypertension and echocardiographic evidence of diastolic dysfunction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(Valsartan + Amlodipine to target SBP of \< 140 mmHg)
Drug: valsartan · Drug: amlodipine
(Valsartan + Amlodipine to target SBP \< 130 mm Hg)
Drug: valsartan · Drug: amlodipine
160 mg or 320 mg tablets once a day
Also known as: Diovan
5 mg or 10 mg tablets once a day
Also known as: Norvasc
Change in Lateral Mitral Annular Myocardial Relaxation Velocity
Change from baseline in lateral mitral annular myocardial relaxation velocity (E') at Week 24
Time frame: Baseline to 24 weeks after treatment
Change in Left Atrial Size
Change from baseline in left atrial size at Week 24
Time frame: Baseline to 24 weeks after treatment
Change in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity
Change from baseline in peak E-wave velocity / lateral mitral annular myocardial relaxation velocity (E/E') at Week 24
Time frame: Baseline to 24 weeks after treatment
Percent Change From Baseline in Vascular Stiffness
Percent change from baseline in Vascular Stiffness (measured by radial augmentation index \[AI\]) at Weeks 8 and 24
Time frame: Baseline to 8 and 24 weeks after treatment
Change in Mean Sitting Systolic Blood Pressure (msSBP)
Change from baseline in msSBP at Weeks 8 and 24
Time frame: Baseline to 8 and 24 weeks after treatment
Change in Mean Sitting Diastolic Blood Pressure (msDBP)
Change from baseline in msDBP at Weeks 8 and 24
Time frame: Baseline to 8 and 24 weeks after treatment
Change in Estimated Central Aortic Pressure
Change from baseline in estimated central aortic pressure at Weeks 8 and 24
Time frame: Baseline to 8 and 24 weeks after treatment
| Milestone | Intensive Treatment Regimen | Standard Treatment Regimen |
|---|---|---|
| Started | 114 | 115 |
| Completed | 95 | 99 |
| Not completed | 19 | 16 |
| Withdrew: Adverse event | 6 | 3 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 1 |
| Withdrew: Protocol deviation | 3 | 1 |
| Withdrew: Patient withdrew consent | 7 | 6 |
| Withdrew: Lost to follow-up | 3 | 5 |
Change from baseline in lateral mitral annular myocardial relaxation velocity (E') at Week 24
| cm/s | Intensive Treatment Regimen | Standard Treatment Regimen |
|---|---|---|
| Change in Lateral Mitral Annular Myocardial Relaxation Velocity | 1.544 ± 1.3946 | 1.476 ± 1.5985 |
Change from baseline in left atrial size at Week 24
| cm | Intensive Treatment Regimen | Standard Treatment Regimen |
|---|---|---|
| Change in Left Atrial Size | -0.127 ± 0.3082 | -0.104 ± 0.2845 |
Change from baseline in peak E-wave velocity / lateral mitral annular myocardial relaxation velocity (E/E') at Week 24
| ratio | Intensive Treatment Regimen | Standard Treatment Regimen |
|---|---|---|
| Change in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity | -0.951 ± 2.1729 | -0.680 ± 2.0714 |
Percent change from baseline in Vascular Stiffness (measured by radial augmentation index \[AI\]) at Weeks 8 and 24
| percentage of change in mean AI | Intensive Treatment Regimen | Standard Treatment Regimen |
|---|---|---|
| Week 8 | -7.89 ± 9.645 | -7.32 ± 11.970 |
| Week 24 | -6.07 ± 10.582 | -5.63 ± 11.367 |
Change from baseline in msSBP at Weeks 8 and 24
| mm Hg | Intensive Treatment Regimen | Standard Treatment Regimen |
|---|---|---|
| Week 8 | -25.74 ± 16.112 | -22.31 ± 16.014 |
| Week 24 | -30.37 ± 18.745 | -25.06 ± 17.074 |
Change from baseline in msDBP at Weeks 8 and 24
| mm Hg | Intensive Treatment Regimen | Standard Treatment Regimen |
|---|---|---|
| Week 8 | -12.77 ± 10.118 | -12.62 ± 10.475 |
| Week 24 | -15.21 ± 10.147 | -14.08 ± 11.163 |
Change from baseline in estimated central aortic pressure at Weeks 8 and 24
| mm Hg | Intensive Treatment Regimen | Standard Treatment Regimen |
|---|---|---|
| Week 8 | -16.30 ± 12.483 | -14.68 ± 12.751 |
| Week 24 | -17.71 ± 14.635 | -14.76 ± 12.689 |
Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intensive Treatment Regimen | — | 3/114 (2.6%) | 49/114 (43%) |
| Standard Treatment Regimen | — | 3/114 (2.6%) | 41/114 (36%) |
| Event | Intensive Treatment Regimen | Standard Treatment Regimen |
|---|---|---|
| Atrial fibrillationCardiac disorders | 1/114 | 0/114 |
| GoitreEndocrine disorders | 1/114 | 0/114 |
| Appendicitis perforatedGastrointestinal disorders | 0/114 | 1/114 |
| Intestinal obstructionGastrointestinal disorders | 0/114 | 1/114 |
| PancreatitisGastrointestinal disorders | 0/114 | 1/114 |
| Cholecystitis acuteHepatobiliary disorders | 0/114 | 1/114 |
| Abdominal abscessInfections and infestations | 0/114 | 1/114 |
| PneumoniaInfections and infestations | 0/114 | 1/114 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/114 | 0/114 |
| Thyroid adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/114 | 0/114 |
| Event | Intensive Treatment Regimen | Standard Treatment Regimen |
|---|---|---|
| Oedema peripheralGeneral disorders | 24/114 | 20/114 |
| DizzinessNervous system disorders | 16/114 | 9/114 |
| FatigueGeneral disorders | 12/114 | 7/114 |
| Upper respiratory tract infectionInfections and infestations | 8/114 | 7/114 |
| HeadacheNervous system disorders | 5/114 | 8/114 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 6/114 | 4/114 |
| Age Continuous(years) | Intensive Treatment Regimen | Standard Treatment Regimen | Total |
|---|---|---|---|
| Mean | 60.2 ± 10.03 | 58.9 ± 9.45 | 59.6 ± 9.74 |
| Sex: Female, Male(Participants) | Intensive Treatment Regimen | Standard Treatment Regimen | Total |
|---|---|---|---|
| Female | 61 | 54 | 115 |
| Male | 53 | 60 | 113 |
The record gives a start of Nov 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Amlodipine